L'ablation d'une tumeur cérébrale en Chine coûte généralement entre $14,000 et $26,000. Le tarif dépend de la complexité, de la technique chirurgicale et de l'établissement choisi. En France, ces interventions avoisinent $27,500 en moyenne. Les patients économisent environ 27% par rapport aux tarifs français. Les devis incluent habituellement l'intervention neurochirurgicale, l'imagerie diagnostique et le séjour hospitalier standard.
Avis d'expert Bookimed : La Chine dispose d'une vaste expertise. L'hôpital Xiamen Humanity soigne 1 000 000 de patients chaque année. Cette échelle considérable favorise la standardisation des protocoles chirurgicaux. Pour les patients internationaux, les hôpitaux tertiaires de Xiamen offrent des soins complets dans 47 départements. Choisir un centre tertiaire à but non lucratif garantit l'accès aux essais cliniques et à la recherche pharmaceutique. Cet environnement propose une infrastructure médicale de haut niveau pour une fraction des coûts occidentaux.
| Chine | Turquie | Espagne | |
| Ablation d'une tumeur cérébrale | ≈ $14,000 | de $12,000 | de $21,500 |
Jour 1
Jour 2
Jour 3
Jour 4-5
Semaine 1-2
Semaine 3-4
Semaine 5-6
Semaine 7-8
Veuillez noter que le délai de récupération de chaque patient varie en fonction des circonstances individuelles.
Li Guiyuan, MD, is Chief Physician in the Department of Medical Oncology at Shanghai Tongji Hospital. He has practiced oncology since 1996 and has more than 20 years of experience. He earned a master’s degree in Oncology from Nanjing University in 2003. He has worked in the hospital’s Oncology Department since then.
His clinical work includes chemotherapy for lung, breast, ovarian, and gastrointestinal cancers. He also provides targeted and anti‑angiogenic therapies for malignant tumours. He manages malignant pleural and peritoneal effusions and bone metastases with multimodal care, including immunotherapy.
He has authored more than 10 basic and clinical papers, including “Tumour Hypoxia and Its Therapeutic Strategies” and “Establishment of Tumour Model with B16 Melanoma Cell Line of C57BL/6 Mice in ICR Mice.” He received the Medical Achievement Award from the General Logistics Department of the PLA for “Research and Application of Early‑diagnosis and Prediction Model for Metastasis of Non‑small‑cell Lung Cancer.” He co‑authored “Evidence‑based Oncology Treatment” and “Handbook of Modern Evidence‑based Diagnosis and Treatment of Cancer.” He has also taken part in key projects of the National Natural Science Foundation of China.